COCP vs. ATNM, ESLA, AADI, RNXT, PDSB, FGEN, OTLK, TPST, NEUP, and NBRV
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Actinium Pharmaceuticals (ATNM), Estrella Immunopharma (ESLA), Aadi Bioscience (AADI), RenovoRx (RNXT), PDS Biotechnology (PDSB), FibroGen (FGEN), Oncobiologics (OTLK), Tempest Therapeutics (TPST), Neuphoria Therapeutics (NEUP), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.
Cocrystal Pharma vs. Its Competitors
Cocrystal Pharma (NASDAQ:COCP) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
Cocrystal Pharma currently has a consensus price target of $6.00, suggesting a potential upside of 471.43%. Actinium Pharmaceuticals has a consensus price target of $4.50, suggesting a potential upside of 190.32%. Given Cocrystal Pharma's higher possible upside, analysts clearly believe Cocrystal Pharma is more favorable than Actinium Pharmaceuticals.
Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 4 mentions for Actinium Pharmaceuticals and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.64 beat Actinium Pharmaceuticals' score of -0.33 indicating that Cocrystal Pharma is being referred to more favorably in the media.
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 28.1% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Actinium Pharmaceuticals' return on equity of -100.85% beat Cocrystal Pharma's return on equity.
Cocrystal Pharma has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.
Summary
Cocrystal Pharma beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:COCP) was last updated on 10/15/2025 by MarketBeat.com Staff
